Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8852W HIGH $2.09
Volume
1.16 M
Value Traded
849.78 K
Short % Float
15.5%
+7.18%Week
-2.55%1 Month
-17.85%3 Month
-34.17%6 Month
-45.38%5 Year
-47.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
251.39 M
EPS (TTM)
-0.13
P/E Ratio
-
Ent. Value
200.56 M
Total Shares
252.75 M
Float Shares
190.16 M
Insiders
24.81%
Institutions
26.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LCTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Lineage Cell Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lineage Cell Therapeutics, Inc.
733Total events
4Upcoming
158Tier-1 (high impact)
2012 to 2043Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedIP / Competition
USPTO issued U.S. Patent No. 12,692,476 covering AlloSCOPE 5D manufacturing platform
●Enrollment UpdateRG6501Trial
Phase 2a GAlette Study currently enrolling at 17 clinical sites in the U.S. and Israel
geographic atrophysource ↗
▲First Patient DosedOPC1Trial
Second chronic SCI participant treated in the DOSED study
spinal cord injurysource ↗
●Trial InitiationOPC1Trial
Opened second clinical site in the DOSED study, Rancho Research Institute
spinal cord injurysource ↗
●Development Candidate NominationCOR1Preclinical
Launched COR1, corneal endothelial cell therapy program
corneal endothelial diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
Met first milestone for ILT1 manufacturing initiative
Type 1 Diabetessource ↗
●Management ChangeCorporate
Appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical
●Quarterly UpdateCorporate
Lineage to report Q2 2026 financial and operating results and provide business update
◆Oral PresentationPresentation
Presentation at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
▲Full ResultsRG6501Clinical Data
Positive 3-year Phase 1/2a clinical data of RG6501 (OpRegen) presented at Retinal Therapeutics Innovation Summit 2026
geographic atrophysource ↗
▲Trial InitiationCOR1Trial
Launched new corneal endothelial disease cell therapy program COR1
corneal endothelial diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
Met first milestone for AlloSCOPE 5D manufacturing initiative (ILT1) at 0.5L scale
Type 1 Diabetessource ↗
▲First Patient DosedOPC1Trial
Second chronic SCI patient treated in DOSED study with OPC1
spinal cord injurysource ↗
▲Trial InitiationTrial
Established Scientific Advisory Board with Joachim Fruebis as founding member
◆Enrollment UpdateRG6501Trial
Phase 2a GAlette study currently enrolling at 17 sites in U.S. and Israel
geographic atrophysource ↗
▲Manufacturing MilestoneReSonanceCMC / Inspection
Completed 3 engineering manufacturing runs for ReSonance
hearing losssource ↗
▲Preclinical PoCReSonancePreclinical
Established novel model of deafening to support ReSonance functional testing
hearing losssource ↗
▲Trial InitiationOPC1Trial
Opened second clinical site (Rancho Research Institute) for DOSED study
spinal cord injurysource ↗
●Development Candidate NominationCOR1Preclinical
Launched New Corneal Endothelial Disease Cell Therapy Program COR1
corneal endothelial diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
Met First Milestone with AlloSCOPE 5D Manufacturing Initiative
Type 1 Diabetessource ↗
▲First Patient DosedOPC1Trial
Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study
spinal cord injurysource ↗
●Management ChangeCorporate
Established Scientific Advisory Board With Joachim Fruebis, PhD as Founding Member
●Enrollment UpdateRG6501Trial
Phase 2a GAlette Study Currently Enrolling at 17 Clinical Sites
geographic atrophysource ↗
●Enrollment UpdateRG6501Trial
Phase 2a GAlette Study currently enrolling at 17 clinical sites in U.S. and Israel
geographic atrophysource ↗
●IND SubmissionOPC1IND
Resubmitted CLIN2 grant application to CIRM for DOSED study
chronic spinal cord injurysource ↗
▲Oral PresentationRG6501Presentation
Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen) Featured at Retinal Therapeutics Innovation Summit 2026
geographic atrophysource ↗
▲Full ResultsRG6501Clinical Data
Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen) Featured at Retinal Therapeutics Innovation Summit 2026
Geographic Atrophysource ↗
▲Oral PresentationRG6501Presentation
Positive RG6501 (OpRegen) Phase 1/2a Clinical Study 36 Month Results featured at Clinical Trials at the Summit 2025
geographic atrophy secondary to age-related macular degenerationsource ↗
▲Partnership / LicenseReSonanceCorporate
Entered research collaboration with William Demant Invest to develop ReSonance (ANP1)
sensorineural hearing losssource ↗
●Manufacturing MilestoneCMC / Inspection
Initiated manufacturing scale project for Type 1 Diabetes cell therapy (islet cell transplants)
▲First Patient DosedOPC1Trial
First chronic spinal cord injury participant treated in DOSED study
chronic spinal cord injurysource ↗
▲Oral PresentationRG6501Presentation
Positive RG6501 (OpRegen) Phase 1/2a 36-month results featured at Clinical Trials at the Summit 2025
geographic atrophy secondary to age-related macular degenerationsource ↗
▲First Patient DosedOPC1Trial
First chronic spinal cord injury patient treated in DOSED study with OPC1
spinal cord injurysource ↗
▲Manufacturing MilestoneCMC / Inspection
Successfully completed GMP production run for two product candidates using cell banking system
▲Runway Guidance UpdateCorporate
Cash runway guidance: expected to support operations into Q1 2027
◆R&D DayPresentation
3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS)
spinal cord injurysource ↗
▲Oral PresentationRG6501Presentation
36-month results presented at Clinical Trials at the Summit 2025
geographic atrophy secondary to age-related macular degenerationsource ↗
◆Enrollment UpdateRG6501Trial
GAlette study currently enrolling
geographic atrophy secondary to age-related macular degenerationsource ↗
◆Oral PresentationRG6501Presentation
RG6501 (OpRegen) Phase 1/2a 36-month results to be presented at CTS 2025
geographic atrophy secondary to age-related macular degenerationsource ↗
●Quarterly UpdateCorporate
Fourth Quarter and Full Year 2024 Financial Results and Business Update
▲Trial InitiationOPC1Trial
Initiated OPC1 Device Delivery Study in Patients with Subacute and Chronic Spinal Cord Injury
subacute and chronic spinal cord injurysource ↗
Past FDA Catalysts and PDUFA Decisions
How LCTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 74%
Micro Cap(rank 489 of 660)
Percentile Rank
Lineage Cell Therapeutics, Inc. faces pipeline headwinds (28/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OPC1 Monoclonal antibodyNCT06841770 | Spinal Cord Injury Cervical | Phase 1 | RECRUITING | 10 | Jun 30, 2037 |
Clinical Trial Results
Readouts, endpoints and source filings for every LCTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RG6501 | Phase 1/2a | 2026-05-12 | sustained gains in best corrected visual acuity (BCVA); partial structural restoration of the retina; re-appearance of an RPE layer; features associated with recovery of photoreceptorsRead More | LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen ) Featured at Retinal Therapeutics Innovation SummiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bradsher Neal CDirector, 10% Owner | Grant/Award | 125,000 125,000 held | $0.00 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LCTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.3 % | 1.13 M | 2.51 M |
LCTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LCTX ranks across every disease it competes in
Competitive Position is a premium feature
See how LCTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLCTX News
LCTXLineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Lineage Cell Therapeutics has announced the issuance of a new patent for its AlloSCOPE 5D manufacturing platform. This development is expected to enhance the company's intellectual property portfolio and strengthen its position in the cell therapy market. The patent could lead to improved manufacturing capabilities for their therapeutic products.
Read more →LCTXLineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Lineage Cell Therapeutics has released its financial results for the second quarter of 2026. The report includes key updates on the company's business activities. Further details on earnings and operational performance were shared in the release.
Read more →LCTXLineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Lineage Cell Therapeutics will report its second quarter 2026 financial results on August 6, 2026, after U.S. market close. The company will also conduct a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This update reflects the company's ongoing commitment to transparency with investors.
Read more →LCTX▼ -5.5%on this news
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Lineage Cell Therapeutics has provided an update on its COR1 program, which is focused on developing allogeneic corneal endothelial cells (CEnCs) for treating corneal endothelial disease. The company aims to create a consistent and scalable supply of CEnCs using its AlloSCOPE manufacturing platform. The program is advancing into in-vivo animal testing, with initial data expected this year. Lineage believes this approach could address the significant shortage of donor corneas globally.
Read more →LCTXLineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Lineage Cell Therapeutics is scheduled to present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit. The event will provide a platform for the company to discuss its advancements and strategies in the biopharmaceutical sector. Further details about the presentation or specific topics were not disclosed in the article.
Read more →LCTXLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Lineage Cell Therapeutics reported its first quarter 2026 financial results, highlighting the launch of its new corneal endothelial cell therapy program, COR1. The company also advanced its OPC1 study for spinal cord injuries and established a Scientific Advisory Board to enhance its cell therapy platform. Despite a positive cash position, the company faces increased operating expenses and ongoing risks in clinical development.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics reported positive first quarter 2026 financial results and updates on various clinical programs. Notable achievements include favorable data from the three-year Phase 1/2a study of RG6501 (OpRegen) presented at a major summit, the launch of a new corneal endothelial cell therapy program, and advancements in their spinal cord injury clinical trials. The company also established a Scientific Advisory Board and met key milestones in their manufacturing initiatives, reflecting their ongoing commitment to developing innovative cell therapies.
Read more →LCTXLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
Lineage Cell Therapeutics will report its first quarter 2026 financial results on May 12, 2026. The company will also host a conference call to discuss these results and provide a business update. Lineage focuses on developing allogeneic cell therapies for serious medical conditions and has several programs in various stages of development.
Read more →LCTX▼ -7.2%on this newsshared move
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Lineage Cell Therapeutics presented 36-month results from its Phase 1/2a study of OpRegen for geographic atrophy at the Retinal Innovation Summit 2026. The study showed significant gains in visual acuity and evidence of retinal structural improvement following a single administration of the therapy. These results suggest potential long-term benefits and challenge the perception of geographic atrophy as an irreversible condition.
Read more →LCTXLineage Announces Formation of Scientific Advisory Board
Lineage Cell Therapeutics has announced the formation of a Scientific Advisory Board (SAB) to guide the development of its cell transplant pipeline. Joachim Fruebis, Ph.D., will serve as the founding member, bringing extensive experience in various therapeutic areas. Additionally, Priyantha Herath, M.D., Ph.D., has been appointed as Senior Vice President and Head of Clinical Operations, enhancing the company's leadership in clinical development.
Read more →LCTXLineage Launches New Cell Therapy Program in Corneal Endothelial Disease
Lineage Cell Therapeutics has announced the launch of its new COR1 program, aimed at treating corneal endothelial disease through a novel cell therapy. This initiative leverages the company's proprietary AlloSCOPE platform to produce allogeneic corneal endothelial cells, addressing the critical shortage of donor corneas. The program is currently in preclinical development, with plans for further updates as progress is made.
Read more →LCTX▼ -5.6%on this news
LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics has reported strong financial results for the fourth quarter and full year 2025, highlighting multiple successes in its RG6501 (OpRegen Cell Therapy) program. The Phase 1/2a clinical trial results have shown sustained improvements in visual acuity for treated patients over 36 months. The company has achieved key milestones with Genentech, validating its manufacturing processes and opening new avenues for treatment, including collaborations aimed at addressing sensorineural hearing loss and Type 1 diabetes. The CEO expressed optimism for further advancements in 2026 with a commitment to evolving their institutional capabilities.
Read more →LCTXLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
Lineage Cell Therapeutics will report its fourth quarter and full year 2025 financial results on March 5, 2026. The company will also host a conference call to discuss these results and provide a business update. Lineage is focused on developing allogeneic cell therapies for serious medical conditions, with several programs in various stages of development.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics reported its third quarter 2025 financial results, highlighting positive 36-month outcomes from the RG6501 (OpRegen) Phase 1/2a study. The company announced a collaboration with William Demant Invest to develop the ReSonance program for hearing loss and revealed plans for a new Type 1 diabetes initiative. Despite the positive developments, the company reported a significant net loss of $29.8 million, along with a decrease in total revenues compared to the previous year. Overall, Lineage continues to focus on advancing its innovative cell therapies while addressing operational challenges.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics reported its second quarter 2025 financial results, highlighting significant advancements in its OpRegen and OPC1 programs. Notable outcomes from the 36-month clinical study of OpRegen showed sustained improvements in visual acuity, challenging previously held beliefs about geographic atrophy. The company also celebrated the first successful treatment of a chronic spinal cord injury patient using a novel delivery system and reported enhancements in its cell production capabilities. However, financial results showed increased losses due to rising operating expenses and impairment costs.
Read more →LCTXOPREGEN (RG6501) 36-MONTH VISUAL ACUITY RESULTS FEATURED AT CLINICAL TRIALS AT THE SUMMIT 2025
Lineage Cell Therapeutics has presented promising 36-month results from their Phase 1/2a study of OpRegen (RG6501) for treating Geographic Atrophy (GA) due to age-related macular degeneration. The data indicate significant vision improvements among patients who received extensive coverage with OpRegen, showing mean gains of +9 letters. Sustained retinal structural improvements were also observed, challenging the notion of irreversible damage from GA. The ongoing GAlette study aims to further explore the treatment delivery methods and efficacy.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics has reported its first quarter financial results for 2025, highlighting optimistic advancements in its clinical studies, particularly with OpRegen. Notable updates include the upcoming presentation of 36-month results from the RG6501 (OpRegen) Phase 1/2a study at the Clinical Trials at the Summit 2025. The company initiated a new clinical study for the OPC1 delivery device, aiming to address spinal cord injuries. Despite some operational losses, revenues increased slightly, reflecting a growing collaboration with Roche.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Lineage Cell Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting positive outcomes from its OpRegen program for patients with geographic atrophy. The company received RMAT designation from the FDA, indicating potential for accelerated development. They announced two financings totaling $44 million and partnered with Genentech to support ongoing drug development. Although revenues increased, the company's operational losses demonstrate a continued financial challenge.
Read more →LCTXLineage Cell Therapeutics Announces CLOSING OF SECOND TRANCHE OF PREVIOUSLY ANNOUNCED Registered Direct Offering
Lineage Cell Therapeutics has successfully closed the second tranche of its registered direct offering, securing an additional $30 million in gross proceeds. The total gross proceeds from both tranches now amount to $66 million, with potential further funding of $36 million dependent on the exercise of warrants linked to clinical milestones. Shareholder approval was received for the issuance of new common shares, reflecting positive investor sentiment towards the company's future potential. However, the company acknowledges certain risks related to the execution of these warrants.
Read more →LCTX▼ -29%on this news
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering $30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Miles
Lineage Cell Therapeutics has announced a registered direct offering of up to $66 million, consisting of $30 million upfront and potential additional proceeds of $36 million from common warrant exercises. The company has entered agreements with institutional investors and Broadwood Partners, an affiliate of a board member. The offering is expected to close on or about November 21, 2024, but is subject to various closing conditions, including shareholder approval for a portion of the sale. Proceeds will be used for working capital, general corporate purposes, and R&D expenses.
Read more →About Lineage Cell Therapeutics, Inc.
Headquarters2173 SALK AVENUE, CARLSBAD, CA, 92008
Founded05-03-1992
BIOPHARMAWATCH ELITE PLUS
Trade the next LCTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime